Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy

Yu, Ziqi; Song, Mei; Chouchane, Lotfi; Ma, Xiaojing

doi:10.3390/cancers13133276

Cited by 8 publications

(7 citation statements)

References 182 publications

(208 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like many cancers, metastasis is the leading cause of breast cancer death. Cancer cell migration and invasion are two key procedures of cancer metastasis (Mahauad-Fernandez et al., 2014 ; Yu et al., 2021 ). Therefore, to determine the ability of PSA-Lip-HNK in suppressing cancer cell migration and invasion, wound healing and Transwell assays were performed.…”

Section: Resultsmentioning

confidence: 99%

Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis

Guan

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

To improve the anti-metastasis effects of honokiol (HNK) on breast cancer, we designed cationic liposomes (Lip) in which HNK was encapsulated into Lip, and its surface was modified with negatively charged polysialic acid (PSA-Lip-HNK) for efficient treatment of breast cancer. PSA-Lip-HNK possessed a homogeneous spherical shape and high encapsulation efficiency. In vitro 4T1 cell experiments indicated that PSA-Lip-HNK increased cellular uptake and cytotoxicity via the endocytosis pathway mediated by PSA and selectin receptors. Furthermore, the significant antitumor metastasis impact of PSA-Lip-HNK was confirmed by wound healing and cell migration and invasion. Enhanced in vivo tumor accumulation of the PSA-Lip-HNK was observed in 4T1 tumor-bearing mice by living fluorescence imaging. For in vivo antitumor experiments using 4T1 tumor-bearing mice, PSA-Lip-HNK exhibited a higher tumor growth and metastasis inhibition compared with unmodified liposomes. Therefore, we believe that PSA-Lip-HNK well combined biocompatible PSA nano-delivery and chemotherapy, providing a promising drug delivery approach for metastatic breast cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis

Guan

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…49 Yu et al have also reported that in BC patients with bone, lung, and brain metastases, actionable mutations frequently occur in the PI3K/AKT/mTOR pathway. 50 Inhibiting the activation of the PI3K/Akt pathway partially restores the sensitivity of trastuzumab-resistant HER2-positive BC cells. 51 In addition, the genetic diversities of BC patients demonstrate that it is important to identify gene signatures with distinct survival and druggable targets.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, angiogenesis is a crucial process in the formation of inflammatory BC (IBC), and genes and proteins involved in angiogenesis are often overexpressed and overactivated in IBC. , Recent studies have shown that hormone receptor (HR) + BC causes the majority of BC-related deaths . Yu et al have also reported that in BC patients with bone, lung, and brain metastases, actionable mutations frequently occur in the PI3K/AKT/mTOR pathway . Inhibiting the activation of the PI3K/Akt pathway partially restores the sensitivity of trastuzumab-resistant HER2-positive BC cells …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment

Ding

Liu

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Objectives: We aim to identify the breast cancer (BC) subtype clusters and the crucial gene classifier prognostic signatures by integrating genomic analysis with the tumor immune microenvironment (TME). Methods: Data sets of BC were derived from the Cancer Genome Atlas (TCGA), METABRIC, and Gene Expression Omnibus (GEO) databases. Unsupervised consensus clustering was carried out to obtain the subtype clusters of BC patients. Weighted gene coexpression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO), and univariate and multivariate regression analysis were employed to obtain the gene classifier signatures and their biological functions, which were validated by the BC dataset from the METABRIC database. Additionally, to evaluate the overall survival rates of BC patients, Kaplan−Meier survival analysis was carried out. Moreover, to assess how BC subtype clusters are related to the TME, single-cell analysis was performed. Finally, the drug sensitivity and the immune cell infiltration for different phenotypes of BC patients were also calculated by the CIBERSORT and ESTIMATE algorithms. Results: TCGA−BC samples were divided into three subtype clusters, S1, S2, and S3, among which the prognosis of S2 was poor and that of S1 and S3 were better. Three key pathways and 10 crucial prognostic-related gene signatures are screened. Finally, single-cell analysis suggests that S1 samples have the most types of immune cells, S2 with more sensitivity to tumor treatment drugs are enriched with more neutrophils, and more multilymphoid progenitor cells are involved in subtype cluster S3. Conclusions: Our novelty was to identify the BC subtype clusters and the gene classifier signatures employing a large-amount dataset combined with multiple bioinformatics methods. All of the results provide a basis for clinical precision treatment of BC.

show abstract

“…Cancer cells metastatic dissemination affecting distal organs is one of the lethal aspects in patients with breast cancer particularly in basal like breast cancer (Huang et al., 2021 ). This type of cancer exhibits the potential of metastasis and extravasations from breast to the lungs and is characterized by overexpression of IL13Rα2 genes (Yu et al., 2021 ). It was reported from a well-characterized cell line model that the expression of IL13Rα2 genes was higher in metastatic cells in comparison with non-metastatic cells that lead to worse metastasis-free survival of patients with high grade tumors (Kalli et al., 2019 ).…”

Section: Il13rα2 In Oncology and Glioblastomamentioning

confidence: 99%

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Liang

Liu

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and concomitant chemo-radiotherapy. In recent years, nanotechnology has shown considerable promise in treating a variety of illnesses, and certain nanomaterials have been proven to pass the blood–brain barrier (BBB) and stay in glioblastoma tissues. Recent preclinical research suggests that the diagnosis and treatment of brain tumor is significantly explored through the intervention of nanomaterials that has showed enhanced effect. In order to elicit an antitumor response, it is necessary to retain the therapeutic candidates within glioblastoma tissues and this job is effectively carried out by nanocarrier particularly functionalized nanocarriers. In the arena of neoplastic diseases including GBM have achieved great attention in recent decades. Furthermore, interleukin-13 receptor α chain variant 2 (IL13Rα2) is a highly expressed and studied target in GBM that is lacked by the surrounding environment. The absence of IL13Rα2 in surrounding normal tissues has made it a suitable target in glioblastoma therapy. In this review article, we highlighted the role of IL13Rα2 as a potential target in GBM along with design and fabrication of efficient targeting strategies for IL13Rα2 through surface functionalized nanocarriers.

show abstract

Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy

Cited by 8 publications

References 182 publications

Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis

Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis

Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Contact Info

Product

Resources

About